Genetic testing advances as insurers balk

Genetic testing offers real insights into how patients should be treated, but insurers have been reluctant to cover the cost of the tests. With a wave of new, more targeted biologics in the pipeline along with new tests to identify the people most likely to benefit from them, look for the issue to heat up considerably in the next few years.

- read the report on genetic testing from the San Jose Mercury News

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.